Editas Medicine Company

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Industry: Atrificial Vectors and Immune Cells
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2013-01-01
Employees Number: 101-250
Funding Status: IPO
Investors Number: 17
Total Funding: 656600000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-01-21
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership